Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Cash from Operations (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Cash from Operations data on record, last reported at 21187000.0 in Q3 2025.

  • For Q3 2025, Cash from Operations fell 73.18% year-over-year to 21187000.0; the TTM value through Sep 2025 reached 74932000.0, down 53.89%, while the annual FY2024 figure was 56015000.0, 51.36% down from the prior year.
  • Cash from Operations reached 21187000.0 in Q3 2025 per ABEO's latest filing, down from 18784000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 5746000.0 in Q3 2023 and bottomed at 30257000.0 in Q4 2021.
  • Average Cash from Operations over 5 years is 13712894.74, with a median of 12684000.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: crashed 1779.32% in 2021, then soared 53.76% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 30257000.0 in 2021, then surged by 53.76% to 13992000.0 in 2022, then skyrocketed by 34.0% to 9235000.0 in 2023, then crashed by 79.31% to 16559000.0 in 2024, then dropped by 27.95% to 21187000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 21187000.0 in Q3 2025, 18784000.0 in Q2 2025, and 18402000.0 in Q1 2025.